DRUG INFORMATION CENTER BULLETIN
FACULTY OF PHARMACY
ASSIUT UNIVERSITY

Ass. Uni. D.I. Bull., Vol.21, No.1, march 2026

AU-PHA-PIC-30-07

كلية الصيدلة

جامعة أسيوط

In This Issue…

Editorial Board

Tel. 088/2080388 & 088/2411556
E-mail: clinipharm_assiut@yahoo.com
Website: www.aun.edu.eg/clinpharm
FB Page: facebook.com/DIC.pharmacy

رقم الايداع: 12632 لسنة 2005

This Bulletin is a free quarterly periodical issued by the Drug Information Center (DIC) located at Faculty of Pharmacy, Assiut University

Cold Agglutinin Disease (CAD)

1. Introduction and Definition



Cold Agglutinin Disease (CAD) is a rare but significant subset of Autoimmune Hemolytic Anemia (AIHA). It is characterized by the presence of cold -reacting primarily Immunoglobulin M (IgM) that bind to red blood cell (RBC) surface antigens. This binding initiates a cascade of events leading to erythrocyte agglutination and premature destruction (hemolysis).

A common complaint among patients with cold agglutinin disease is painful fingers and toes with purplish discoloration associated with cold exposure. In chronic cold agglutinin disease, the patient is more symptomatic during the colder months.

2. Epidemiology

Cold agglutinin disease most commonly affects adults who are of middle age and older. Some studies also report a slight bias in favor of females in the incidence of cold agglutinin disease, particularly in older populations. People with infectious mononucleosis, lymphoproliferative diseases, or mycoplasma pneumonia are more susceptible to this condition. Cold agglutinin disease represents an estimated 16–32% of autoimmune hemolytic anemia, whose annual incidence is estimated to be between 1/35,000-1/80,000 in North America and Western Europe. In patients with infectious mononucleosis, more than 60% of whom develop cold agglutinins disease.

3. Classification and Etiology

CAD is broadly classified into primary and secondary forms based on the presence or absence of an underlying systemic condition.

3.1 Primary Cold Agglutinin Disease

Primary CAD is recognized as a low-grade clonal lymphoproliferative disorder of the bone marrow. It is idiopathic, chronic, and typically affects older adults (peaking in the 7th and 8th decades).

- **Genetic Factors:** Cytogenetic studies often reveal trisomy 3, trisomy 12, or the translocation.
- **Clonality:** It involves a B-cell clone that produces monoclonal IgM with kappa light chain restriction, specifically encoded by the $V_{H4\text{-}34}$ gene segment.

3.2 Secondary Cold Agglutinin Syndrome (CAS)

Secondary CAS is a manifestation of an underlying disease. It can be transient (acute) or chronic.

- **Infections:**
  - Mycoplasma pneumoniae: Frequently causes a polyclonal IgM response.
  - Viral: Infectious Mononucleosis (EBV), CMV, HIV, Influenza, and Rubella.
- **Malignancies:** Associated with B-cell neoplasms such as Waldenström macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), and various B-cell lymphomas.
- **Other Associations:** Systemic sclerosis, Hyperreactive Malarial Splenomegaly (HMS), and rare cases following DPT vaccination.

4. Pathophysiology and Mechanism of Hemolysis



The pathophysiology of CAD is a two-stage process involving antibody binding in the periphery and complement-mediated destruction in the core.

4.1 Agglutination and Temperature

IgM is a large pentameric molecule. In the cooler temperatures of the extremities (fingers, toes, ears), IgM binds to the I/i antigens on the RBC membrane. Because of its pentameric shape, a single IgM molecule can bridge multiple RBCs, causing visible clumping (agglutination).

4.2 The Complement Cascade

Once IgM binds to the RBC, it fixes the C1 complex, which activates the classical complement pathway:

1. **C3b Deposition:** C3 is cleaved into C3b, which coats the RBC.
2. **Dissociation:** When the RBC returns to the warmer core, the IgM antibody dissociates and returns to the plasma, but the C3b remains "fixed" to the cell surface.
3. **Extravascular Phagocytosis:** Macrophages in the liver have receptors for C3b. They recognize these coated RBCs and remove them from circulation.
4. **Self-Limiting Nature:** Over time, C3b is converted to C3dg. Macrophages do not recognize C3dg, meaning these cells are "protected" from further destruction, often leading to a plateau in the severity of the anemia.

5. Clinical Manifestations:

The clinical presentation of CAD is dominated by the physical effects of agglutination and the systemic effects of anemia.

- **Acrocyanosis:** Patients experience a purplish discoloration of the skin in distal areas (fingers, toes, nose). Unlike Raynaud's Phenomenon, which is vasospastic, this is caused by the actual physical occlusion of small vessels by clumped RBCs.
- **Hemolytic Anemia:** Fatigue, pallor, and jaundice. Hemolysis is often exacerbated by cold weather or febrile illnesses (which increase complement levels).
- **Hemoglobinuria:** In rare cases of high-titer antibodies, intravascular hemolysis can occur, leading to dark urine.
- **CANOMAD Syndrome:** A rare neurological variant involving ataxia and ophthalmoplegia associated with IgM paraproteins.

6. Diagnosis

Blood tests for diagnosing hemolytic anemia include:

A complete blood count (CBC): A CBC provides detailed information about your red blood cells that can be used to diagnose hemolytic anemia. It shows how many red blood cells you have, their size and your hemoglobin level. Hemoglobin is an important protein that allows your red blood cells to transport oxygen.



A reticulocyte count: A reticulocyte count measures how many immature red blood cells (reticulocytes) you have. Your body may produce a higher-than-normal amount of reticulocytes if your immune system destroys mature red blood cells.

Serum levels tests: High levels of lactate dehydrogenase (LDH) and bilirubin and low levels of haptoglobin are signs of hemolytic anemia.

Your healthcare provider will check for the autoantibody that attacks your red blood cells to determine if your hemolytic anemia is CAD. Tests include:

Direct Coombs test (DAT): The Coombs test checks for autoantibodies associated with CAD. During the test, your red blood cells are separated from the other parts of your blood and placed in a controlled environment. A special solution is added. If the cells clump together (agglutinate) with the solution, the test is positive for the autoantibody.

Cold agglutinin titer test: This test checks how concentrated the autoantibodies are, or how many of them you have. A high concentration of autoantibodies is a sign of CAD.

Once your healthcare provider confirms your diagnosis, they'll explore whether your CAD is related to an underlying condition (secondary cold agglutinin disease).

7. Therapeutic Management Strategies

Management depends on the severity of the anemia and whether the disease is primary or secondary.

7.1 Non-Pharmacological Management

The cornerstone of therapy for mild cases is cold avoidance. This includes wearing thermal clothing, avoiding cold beverages, and maintaining a warm home environment.

7.2 Pharmacological Interventions

- **Rituximab:** The most common first-line therapy. It targets the B-cell clone responsible for IgM production. It has an approximately 50% response rate.
- **Sutimlimab:** A breakthrough C1s inhibitor (FDA-approved in 2022). It halts the classical complement pathway directly, rapidly stopping hemolysis.
- **Complement Inhibitors:** Eculizumab (C5 inhibitor) and Pegcetacoplan (C3 inhibitor) are used in specific or refractory cases.

7.3 Emergency and Support Measures

- **Plasmapheresis:** Highly effective for acute crises because IgM is largely confined to the intravascular space.

- **Transfusion:** Reserved for severe anemia. Crucially, the patient and the blood must be kept warm using specialized **blood warmers** to prevent the antibodies from binding to the donor cells during infusion.

- **Erythropoietin (rhEPO):** Used to stimulate RBC production in patients with an inadequate bone marrow response.

8. Prognosis

The long-term outlook (prognosis) for people with cold agglutinin disease varies based on many factors including the severity of the condition, the signs and symptoms present in each person and the underlying cause. For example, people with cold agglutinin disease caused by bacterial or viral infections tend to have an excellent prognosis; in these cases, the symptoms typically disappear within 6 months after the infection has resolved. Mild to moderate primary (unknown cause) cold agglutinin disease can also be associated with a good prognosis if excessive exposure to the cold is avoided. Those with cold agglutinin disease caused by HIV infection or certain types of cancer generally have a poor prognosis due to the nature of the underlying condition.

References

- **Berentsen, S.** (2016). "How I treat cold agglutinin disease." *Blood*, 127(25): 2941-2951. (The primary source for clinical management and diagnostic criteria).
- **Swiecicki, P. L., et al.** (2013). "Cold agglutinin disease: The Mayo Clinic experience." *Mayo Clinic Proceedings*, 88(10): 1086-1092. (The definitive study on underlying causes and patient demographics).
- **Röth, A., et al.** (2021). "Sutimlimab in Cold Agglutinin Disease." *New England Journal of Medicine*, 384(14): 1323-1334. (Source for the latest FDA-approved complement inhibitor data).

Seasonal Affective Disorder (SAD)

1. Introduction

Seasonal Affective Disorder (SAD) is a recurrent major depressive disorder with a seasonal pattern, typically characterized by episodes beginning in autumn or winter and remitting in spring. Far from being a simple mood shift, SAD is a complex interaction of genetic, environmental, and neurobiological factors triggered by the reduction of photoperiod (daylight hours).

2. Neurobiological Pathophysiology

The "Phase-Shift" hypothesis is the leading explanation for SAD, suggesting that the body's internal clock becomes desynchronized from the external environment.

- **Circadian Rhythm Disruption:** The **Suprachiasmatic Nucleus (SCN)** in the hypothalamus regulates our 24-hour cycle. In SAD patients, the lack of morning light causes a "phase delay," where the body's biological night lasts longer than the actual night.

- **The Serotonin Transporter (SERT):** Serotonin is a key neurotransmitter for mood regulation. Studies using PET scans have shown that SAD patients have higher levels of the Serotonin Transporter protein in winter. This protein removes serotonin from the neural synapse, leading to lower active serotonin levels.
- **Melatonin Overproduction:** Produced by the pineal gland, melatonin signals the body to sleep. In SAD, the onset of melatonin production is often delayed or prolonged, leading to the "hypersomnia" (excessive sleepiness) and lethargy characteristic of the disorder.

3. Clinical Indicators and "Atypical" Symptoms

Unlike standard depression, which often causes insomnia and loss of appetite, SAD is marked by "atypical" vegetative symptoms:

- **Hypersomnia:** Significant difficulty waking up and increased total sleep time.
- **Carbohydrate Craving:** A specific drive for starch and sugar, likely an attempt by the body to increase serotonin synthesis.
- **Social Withdrawal:** Often referred to as "hibernation behavior."

4. Clinical Diagnosis

Even with a thorough evaluation, it can sometimes be difficult for your health care provider or mental health professional to diagnose seasonal affective disorder because other types of depression or other mental health conditions can cause similar symptoms.

To help diagnose SAD, a thorough evaluation generally includes:

- **Physical exam.** Your health care provider may do a physical exam and ask in-depth questions about your health. In some cases, depression may be linked to an underlying physical health problem.
- **Lab tests.** For example, your health care provider may do a blood test called a complete blood count (CBC) or test your thyroid to make sure it's functioning properly.
- **Psychological evaluation.** To check for signs of depression, your health care provider or mental health professional asks about your symptoms, thoughts, feelings and behavior patterns. You may fill out a questionnaire to help answer these questions.

5. Comprehensive Treatment Modalities

The management of SAD is highly effective when it targets the underlying light-deficiency.

A. Bright Light Therapy (BLT)

BLT is the "gold standard" for SAD. It involves exposure to a light box providing **10,000 lux** of cool-white fluorescent light.

- **Mechanism:** It mimics natural sunlight to suppress melatonin and trigger serotonin release.
- **Dosage:** 20–30 minutes daily, ideally within the first hour of waking.

B. Cognitive Behavioral Therapy (CBT-SAD)

Recent research shows that "Winter-targeted" CBT is as effective as light therapy in the short term and actually **more effective** in preventing recurrence in future winters.

C. Pharmacotherapy

Selective Serotonin Reuptake Inhibitors (SSRIs), such as Sertraline or Fluoxetine, are effective for patients who do not respond to light therapy alone.

References

- "Cold Agglutinin Disease: Practice Essentials, Pathophysiology, Etiology". Medscape Reference. 2019-02-02. Retrieved 2019-02-09.
- Melrose, S. (2015). "Seasonal Affective Disorder: An Overview of Assessment and Treatment Strategies." Depression Research and Treatment.
- Berentsen, S., et al. (2006). "Cold agglutinin-mediated autoimmune hemolytic anemia in Norway." Blood. (Comparative data for incidence/prevalence in Norway vs. Italy).

Real Enquiries

At the " Drug Information Center" we respond to enquiries from the professional health team as well as from others. Here's one of the enquiries received at the center

Inquiry: If Velosef Safe during breast - Feeding ?

The answer:

This medicine Passes into breast milk in Small amounts that are unlikely to be harmful to the nursing infant. It should be used with Caution in breast Feeding mothers. Seek medical device from your doctor.

Sources

Cephradine." *Drugs and Lactation Database (LactMed)*. National Institute of Child Health and Human Development. Updated 2024.

Test Your Knowledge

1.An IV order requires 5 million units of sodium penicillin G to be added to 1 L of normal saline. How many mEq of sodium are available per liter of solution?

A. 154.0 mEq C. 8.4 mEq

B. 1540.0 mEg D. 162.0 mEg

2. An order calls for 500 cc of a solution of potassium sulfate to be made so that it contains 10 mEq of Kt. How many grams of potassium sulfate are required?

A. 0.440 g C. 0.044 g
B. 4.440 g D. 0.870 g

3. How many milliliters of a 10% KCl (MW 74.6) solution contain 5.0 mEg of Kt?

A. 2.100 mL C. 3.730 mL
B. 21.000 mL D. 37.300 mL

4. One hundred milligrams (100 mg) of a drug are given as an IV bolus. The drug fits a one-compartment, first-order pharmacokinetic model. The volume of distribution is 20 L. The plasma concentration immediately after administration (at time 0) is

A. 5 mg/L C. 2 mg/cc
B.10 mg/cc D. 15 mg/cc

Ask the expert

Does regular use of proton pump inhibitors increase the risk of nutrient deficiencies?

Regular, long-term use of proton pump inhibitors may increase the risk of certain nutrient deficiencies, particularly vitamin B12, magnesium, calcium, and iron. This effect is mainly related to reduced gastric acid secretion, which can impair nutrient absorption. While the risk is generally low in short-term use, prolonged therapy should be periodically reviewed, especially in individuals with additional risk factors, and appropriate monitoring may be considered.

Clinical studies suggest that the risk of deficiency is generally low in short-term therapy, but it may become more significant with prolonged or high-dose PPI use, particularly in older adults or patients with additional risk factors such as malnutrition, gastrointestinal disorders, or concurrent use of other medications affecting absorption. Hypomagnesemia, although uncommon, has been reported in patients receiving PPIs for extended periods and may lead to neuromuscular or cardiovascular complications.

Answers:

1.(D) 2.(D) 3.(c) 4.(A)